How to Choose a CRO: A Practical Selection Framework for Drug Developers

How do I choose a CRO for preclinical studies?

Choosing a CRO is a comparison, not a hunch. Write your scope down before you email a single vendor: study type, species, endpoints, regulatory intent, and the date you actually need the final report in hand. Then run two or three CROs through the same questions so you're comparing like with like instead of being sold three different stories.

Score them. Pick the dimensions that matter for your program, weight them, and write the numbers down as you go. For IND-enabling work, regulatory intent usually swamps everything else, so a slightly pricier GLP shop with a clean inspection record beats a cheaper lab that's never supported a submission. Those scoring notes aren't busywork either. They become part of your vendor-selection record when a sponsor or partner asks how you picked.

One more thing up front: don't let price drive the decision. A botched or non-compliant safety study can force a full repeat, and a repeat 28-day GLP tox study is months of calendar time you don't get back. The cheap quote is rarely the cheap outcome.

• Write the scope (study type, species, endpoints, regulatory intent, deadline) before contacting anyone
• Send the same RFP to two or three CROs and score them on one scale
• Weight regulatory compliance highest for IND-enabling studies
• Keep the scoring notes; they're your selection audit trail

What questions should I ask a CRO before signing?

The questions that separate vendors are specific, not generic. How many studies of exactly this type have you run? How many supported an IND or BLA that the FDA accepted? When was your last FDA inspection, what Form 483 observations came out of it, and what did you do about them? A confident shop answers these without flinching.

Push past the sales rep. You want to meet the study director who'll actually run the work, not just the business-development person who closes the deal. Ask whether any portion gets subcontracted and how that vendor is qualified, because subcontracted bioanalysis or histopathology is where accountability tends to leak. And ask what their realistic lead time to study start is, in writing, not the optimistic number that wins the bid.

Treat the proposal stage as a free trial. If a CRO is slow, vague, or evasive while they're trying to win you, that's exactly how they'll behave once your study is in-life.

• How many comparable studies have you completed, and how many supported an accepted submission?
• What were your last FDA inspection findings, and what corrective actions followed?
• Who is the named study director, and can I meet them before award?
• Is anything subcontracted, and how is that subcontractor qualified?

Does the CRO have the right capabilities and therapeutic fit?

A CRO that's never run your assay isn't a service provider, it's a science experiment on your dime. Confirm they've done your specific study type, in your modality, in your therapeutic area. Ask for redacted example reports and the credentials of the scientists who'd be on your project, not the company's marquee names.

Modality drives everything downstream. Small molecules, monoclonal antibodies, ADCs, cell and gene therapies, and oligonucleotides each carry their own analytical and safety baggage, and a lab that's excellent at small-molecule tox may be a beginner at a CAR-T potency assay. For preclinical oncology and IND-enabling toxicology specifically, ask how many comparable programs the team has finished and how many cleared a regulatory review.

• Has this team run your exact study type, species, and modality before?
• Which named scientists and study director would staff your program?
• Can they share redacted reports from a comparable project?
• How many of their similar studies actually supported an IND or NDA/BLA?

Is the CRO compliant with GLP, GMP, or GCP for your study?

Match the standard to the work. GLP (Good Laboratory Practice, 21 CFR Part 58, with the OECD GLP principles as the international counterpart) governs non-clinical safety studies meant to support an IND. GMP governs the manufacture of drug substance and product. GCP (ICH E6) governs human trials. The same PK or tox study can be GLP or non-GLP depending entirely on whether it's destined for a regulatory submission, so state your intent before the protocol is drafted, not after.

Compliance is checkable, so check it. Ask how many GLP studies they've run, how many fed an accepted submission, and the specifics of their most recent FDA inspection. A shop running GLP work must operate an independent Quality Assurance Unit that reports outside the study team. That's a Part 58 requirement, not a premium feature, and a CRO that's fuzzy about its QAU is a CRO to be wary of.

• GLP for preclinical safety, GMP for manufacturing, GCP for clinical work
• State regulatory intent so GLP vs non-GLP is settled up front
• Request the latest FDA inspection result and any Form 483 observations
• Confirm an independent Quality Assurance Unit oversees GLP studies

Can the CRO meet your capacity and timeline?

A brilliant CRO that's fully booked will still blow your dates. Ask where your study sits in the queue, the lead time to start, and how they handle it when a bigger client's program collides with yours. Get the timeline broken into milestones (protocol finalization, in-life, analysis, draft report, final report) so a vague six-month promise turns into something you can hold them to.

Be suspicious of any timeline that's dramatically faster than the rest of your shortlist with no reason attached. Over-optimism plus under-planning is one of the more reliable predictors of a study that slips. Get the capacity commitment into the statement of work, not just a handshake on a sales call, and confirm GLP work doesn't get quietly deprioritized behind non-GLP studies that move faster.

• What is the realistic lead time to study start, in writing?
• Break the schedule into milestones with named deliverables
• Ask what usually causes slippage and how they protect your dates
• Get capacity into the SOW, not just a verbal promise

What quality systems and audit history does the CRO have?

Quality systems are the line between a study a regulator accepts and one they bin. Confirm current SOPs aligned to the relevant standard, controlled documentation, trained staff with maintained training records, and data-integrity controls following ALCOA (attributable, legible, contemporaneous, original, accurate). For anything data-heavy, confirm computer system validation and 21 CFR Part 11 compliance for electronic records and signatures.

Then ask the uncomfortable question: will you host a pre-award sponsor audit? A CRO that opens its doors and hands over its inspection history is telling you it's confident. One that stalls is telling you something too. Ask for the audit and inspection trail directly, and cross-check anything they claim against public records where you can.

• Current SOPs, controlled documents, and maintained training records
• Data-integrity controls following ALCOA principles
• Willingness to host a sponsor audit before award
• 21 CFR Part 11 compliance for electronic records where it applies

What are the red flags when choosing a CRO?

Most program disasters announce themselves early if you're watching. The classic is the bait-and-switch: you fall for the A-team at the bid defense, then a junior crew you've never met runs the actual study. Ask, in writing, exactly who will be on your project and whether that team is committed.

Other tells: timelines that look too good with nothing behind them, reluctance to share inspection findings or host an audit, surprise change orders that weren't flagged at kickoff, and status reporting that's either absent or buried in an inbox. Data captured in spreadsheets where a validated system belongs is another one. None of these is automatically fatal, but two or three together is a pattern, and a CRO mismatch is the kind of expensive mistake some early-stage programs never recover from.

If you're already mid-study and seeing these signs, that's when sponsors start quietly pricing a rescue CRO. Better to catch it during selection than during a salvage.

• Bait-and-switch: the A-team at the pitch, a B-team on your study
• Suspiciously fast timelines with no track record behind them
• Resistance to audits, references, or sharing inspection history
• Surprise change orders and thin or missing status reporting

How much does a preclinical CRO cost, and is the pricing transparent?

Insist on an itemized quote. A single headline number hides the things that actually move your budget: pass-through and animal costs, GLP surcharges (the QA auditing, archiving, calibration, and SOP overhead that GLP demands), data-management fees, and repeat-test charges. Two CROs quoting 'the same' study can be 30% apart once you line the items up, and the cheaper headline is sometimes the more expensive program.

Pin down change orders before you sign. What triggers one, how is out-of-scope work priced, and who has to approve it? That's where budgets quietly bleed. Some CROs now offer milestone-linked pricing that defers a slice of the fee until a deliverable lands, which can help conserve runway and align incentives. Whatever the model, get it itemized and get it in the contract.

• Require a line-item quote covering pass-through, animal, and GLP-surcharge costs
• Clarify what triggers a change order and how out-of-scope work is priced
• Watch for repeat-test and data-management fees excluded from the headline
• Ask whether milestone-based or pay-on-deliverable pricing is available

How do I protect IP and verify references before committing?

Get a CDA signed before you share anything sensitive, full stop. Then read the master contract for who owns what: it should assign all study data, results, and inventions to you as the sponsor. Check confidentiality scope, data-retention and return obligations, publication rights, and any non-compete or non-circumvention language before signing, not after a dispute.

References turn marketing into evidence, so actually call them. Ask sponsors with comparable programs the blunt questions: did they hit the timeline, how did they handle the first thing that went wrong, was the final report submission-ready, and would you hire them again? Cross-check the inspection history they describe against anything public.

This is also where being able to see a vendor before you talk to them helps. Enterprise marketplaces like Scientist.com and Science Exchange run private, largely demo- or sales-gated networks aimed at big-pharma buyers. BioBridgeX works differently: CRO and CDMO profiles are openly listed at [biobridgex.com/vendors](https://biobridgex.com/vendors) so you can shortlist before any sales call. As a neutral, all-indications vendor of record across discovery, preclinical, IND-enabling, clinical, and CMC work, BioBridgeX handles vendor qualification, one contract, project management, and milestone-based payments. It's free for buyers, and you can get matched at [biobridgex.com/register](https://biobridgex.com/register).

• Sign a CDA before sharing structures, sequences, or protocols
• Confirm the contract assigns all data, results, and IP to you as sponsor
• Call two or three references and ask about timelines and submission-ready reports
• Browse open vendor profiles at biobridgex.com/vendors before you commit